Darunavir Ethanolate is also known by it’s brand name Prezista, and is used to treat HIV infection. In the class of protease inhibitors, darunavir ethanolate was approved by the FDA in June of 2006. What makes darunavir ethanolate unique is it’s ability to combat drug resistant strains of HIV in affected patients, as well as being efficacious when combined with other antiretroviral agents, such as ritonavir. Treatment with ritonavir is always recommended when taking darunavir ethanolate. While darunavir ethanolate does not cure HIV infection or AIDS, it reduces the amount of the “viral load” or HIV in the blood, and increases the CD4 (T) cell count. As HIV infection is known to destroy CD4 (T) cells, which in turn are crucial to the immune system, the ability of darunavir ethanolate to increase the CD4 (T) cell count is formidable in the treatment of AIDS. The risk of death and additional infections for patients with HIV infection is lessened with the treatment of darunavir ethanolate, thus providing a better quality of life for these patients.
The brand of darunavir ethanolate, which is Prezista, is marketed by Janssen, and trademarked by Tibotec, Incorporated. Prezista is commonly taken alongside Norvir (ritonavir), once daily, at the same time each day. Prezista is an integral part of the AIDS/HIV treatment combination. Darunavir ethanolate is offered as Prezista in tablet form in doses of 75, 150, 300, 400 and 600 milligrams. Patients are typically instructed to take darunavir ethanolate with food, and swallow as a whole tablet with either a full glass of milk or water. Prezista is prescribed to both adult and adolescent patients, ages six and older. Patients allergic to ritonavir should not take darunavir ethanolate or Prezista. Adverse effects of darunavir ethanolate are usually hyperglycemia, changes in the distribution of body fat, diarrhea, nausea, rash, headache, vomiting and rarely, life threatening liver problems.
In October of 2011 the FDA approved a label change for Prezista, adding data from a 192-week study deemed ARTEMIS. This study evaluated the efficacy and safety of both Prezista and ritonavir versus lopinavir and other antiretrovirals in patients with treatment-naive HIV-1. Positive results were indicated, showing that 70% of the patients in the Prezista combination arm reached an undetectable viral load of less than 50 copies/m. versus only 61% of patients in the lopinavir combination arm. The tolerability and safety of Prezista in this study was apparent, with no serious side effects noted. As one of the most prescribed antiretroviral agents in the protease inhibitor class, this study confirms the success of darunavir ethanolate as a treatment for patients with HIV/AIDS.
LGM Pharma supplies Darunavir Ethanolate, CAS# 635728-49-3 for research and development, and assists clients throughout the entire R&D process.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.